导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 23.92% | 261/4773 |
| 近一周 | 0.79% | 853/5467 |
| 近一月 | -8.76% | 3985/5421 |
| 近一季 | -15.98% | 4260/5238 |
| 近半年 | 24.08% | 186/4931 |
| 近一年 | 26.31% | 264/4400 |
| 近两年 | 149.74% | 236/2954 |
| 近三年 | 104.77% | 135/2253 |
| 成立以来 | 73.34% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.68% 3344/4961 |
72.77% 230/5312 |
- - |
- - |
| 2025 | 48.55% 522/4813 |
- 2014/3635 |
3.66% 966/4076 |
48.50% 373/4524 |
-3.49% 3284/4813 |
| 2024 | 11.61% 1309/3463 |
-4.52% 1693/2808 |
-4.48% 1513/3014 |
15.27% 1766/3129 |
6.17% 540/3463 |
| 2023 | 0.73% 393/2656 |
15.22% 217/2280 |
-1.90% 539/2385 |
-9.42% 1818/2515 |
-1.61% 345/2655 |
| 2022 | -32.52% 1678/2207 |
-20.29% 1534/1919 |
-4.37% 1851/2016 |
-15.74% 1339/2113 |
5.07% 488/2208 |
| 2021 | -3.15% 890/1822 |
-8.59% 1089/1255 |
13.65% 280/1330 |
-11.83% 1279/1466 |
5.73% 271/1822 |
| 2020 | 42.70% 258/1250 |
4.66% 63/1028 |
25.53% 152/1067 |
0.21% 1043/1164 |
8.38% 674/1184 |
| 2019 | - - |
- - |
- - |
- - |
10.12% 161/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4546 | 31.90% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.3128 | 30.52% |
| 中欧中证港股通创新药指数发起A | 1.6103 | 30.52% |
| 嘉实中证港股通创新药指数发起式C | 0.8566 | 30.50% |
| 中欧中证港股通创新药指数发起C | 1.4583 | 30.44% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8927 | 30.26% |
| 景顺长城中证港股通创新药ETF联接C | 1.4696 | 29.97% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8736 | 29.94% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8719 | 29.88% |
| 华宝科技ETF联接A VS. 长安沪深300非周期A(740101) |